ATE513050T1 - Rekombinante genmedizin aus adenovirusvektor und gen p53 zur behandlung proliferativer erkrankungen - Google Patents

Rekombinante genmedizin aus adenovirusvektor und gen p53 zur behandlung proliferativer erkrankungen

Info

Publication number
ATE513050T1
ATE513050T1 AT04731832T AT04731832T ATE513050T1 AT E513050 T1 ATE513050 T1 AT E513050T1 AT 04731832 T AT04731832 T AT 04731832T AT 04731832 T AT04731832 T AT 04731832T AT E513050 T1 ATE513050 T1 AT E513050T1
Authority
AT
Austria
Prior art keywords
gene
adenovirus vector
medicine
human
proliferative diseases
Prior art date
Application number
AT04731832T
Other languages
English (en)
Inventor
Zhaohui Peng
Xiaozhi Zhang
Original Assignee
Zhaohui Peng
Xiaozhi Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30122572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513050(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhaohui Peng, Xiaozhi Zhang filed Critical Zhaohui Peng
Application granted granted Critical
Publication of ATE513050T1 publication Critical patent/ATE513050T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT04731832T 2003-05-10 2004-05-09 Rekombinante genmedizin aus adenovirusvektor und gen p53 zur behandlung proliferativer erkrankungen ATE513050T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB031251293A CN1327899C (zh) 2003-05-10 2003-05-10 腺病毒载体与p53基因的基因重组体的应用
PCT/CN2004/000458 WO2004104204A1 (en) 2003-05-10 2004-05-09 RECOMBINANT GENE MEDICINE OF ADENOVIRUS VECTOR AND GENE p53 FOR TREATING PROLIFERATIVE DISEASES

Publications (1)

Publication Number Publication Date
ATE513050T1 true ATE513050T1 (de) 2011-07-15

Family

ID=30122572

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731832T ATE513050T1 (de) 2003-05-10 2004-05-09 Rekombinante genmedizin aus adenovirusvektor und gen p53 zur behandlung proliferativer erkrankungen

Country Status (9)

Country Link
US (1) US20090215164A1 (de)
EP (1) EP1642981B1 (de)
JP (1) JP4695086B2 (de)
KR (1) KR100880701B1 (de)
CN (1) CN1327899C (de)
AT (1) ATE513050T1 (de)
AU (1) AU2004240968B2 (de)
CA (1) CA2525304A1 (de)
WO (1) WO2004104204A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004217830B2 (en) * 2003-03-06 2008-01-24 Zhaohui Peng A recombinant constructed by a virus vector and a human tumor suppressor gene and its use
ES2358204T3 (es) * 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
CN1966683B (zh) * 2005-11-17 2010-05-12 王尚武 表达新型肿瘤抑制基因p53的重组腺病毒
CN102586327B (zh) * 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
CN110055227A (zh) * 2019-03-13 2019-07-26 中国人民解放军第四军医大学 用于增生性瘢痕治疗的野生型p53腺病毒及纯化的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
AU4502096A (en) * 1994-11-11 1996-06-06 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
JP2001515493A (ja) * 1997-03-14 2001-09-18 セレクティブ ジェネティックス，インコーポレイテッド 改変された親和性を有するアデノウイルスベクター
ES2339421T3 (es) * 1997-11-19 2010-05-20 Georgetown University Administracion genica mediante liposoma dirigido.
AU3208699A (en) * 1998-03-27 1999-10-18 Johns Hopkins University, The P40 protein acts as an oncogene
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
CN1177057C (zh) * 2002-05-08 2004-11-24 彭朝晖 病毒载体与人肿瘤抑制基因的重组体及其应用

Also Published As

Publication number Publication date
KR100880701B1 (ko) 2009-02-02
EP1642981B1 (de) 2011-06-15
EP1642981A1 (de) 2006-04-05
JP2007504274A (ja) 2007-03-01
CN1327899C (zh) 2007-07-25
AU2004240968A1 (en) 2004-12-02
JP4695086B2 (ja) 2011-06-08
CA2525304A1 (en) 2004-12-02
WO2004104204A1 (en) 2004-12-02
US20090215164A1 (en) 2009-08-27
CN1471977A (zh) 2004-02-04
AU2004240968B2 (en) 2008-04-17
KR20060029216A (ko) 2006-04-05
EP1642981A4 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE510558T1 (de) Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE602004030353D1 (de) Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
MXPA05003829A (es) Implantacion de materiales biologicos encapsulados para el tratamiento de enfermedades.
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
EP1642981A4 (de) Rekombinante genmedizin aus adenovirusvektor und gen p53 zur behandlung proliferativer erkrankungen
CY1114002T1 (el) Κοντα βιοδραστικα πεπτιδια για κυτταρικη και ανοσολογικη τροποποιηση
DE60038508D1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DK1587828T3 (da) Defensivproteiner
ES2194794T3 (es) Dendrimeros fosforados como agentes de transfeccion.
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
Yao Bee acupuncture: Navigating the sting of traditional medicine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties